-
Immunochina Pharmaceuticals Raises Series E Funding for CAR-T Therapy IM19
•
Beijing-based biotech Immunochina Pharmaceuticals has reportedly raised “hundreds of millions” of renminbi in a Series E financing round. The round was led by BTH Coordinated Development Industrial Investment Fund, with contributions from Taiping Medical and Health Industry Equity Investment Fund, Beijing Science and Technology Innovation Group, Beijing Sun-Novo Pharmaceutical Research…
-
Immunochina Pharmaceuticals and Cell Store Partner to Advance Cell Therapy Commercialization in China
•
Beijing-based firms Immunochina Pharmaceuticals and Cell Store have announced a strategic partnership aimed at bolstering the industrialization and commercialization of cell therapies in China. The financial details of the collaboration have not been disclosed. Innovative Cryopreservation Technology from Cell StoreCell Store is an innovative biotech company that specializes in “controlled…
-
Immunochina Pharmaceuticals’ IM19 CAR-T Therapy Accepted for Review by NMPA
•
Beijing-based biotech company Immunochina Pharmaceuticals has announced that the National Medical Products Administration (NMPA) has accepted for review the New Drug Application (NDA) for its chimeric antigen receptor T cell (CAR-T) product, IM19. The therapy is being sought for the treatment of relapsed or refractory diffuse large B-cell lymphoma (r/r…
-
Sun-Novo Pharmaceuticals Gets Green Light for CAR-T Therapy Clinical Trial in Lupus Treatment
•
Beijing Sun-Novo Pharmaceutical Research Co., Ltd. (SHA: 688621) has secured approval from China’s National Medical Products Administration (NMPA) to initiate clinical trials for ZM001, a CD19-targeted chimeric antigen receptor (CAR)-T therapy, in the treatment of systemic lupus erythematosus (SLE). The therapy, co-developed with Beijing-based gene therapy specialist Immunochina Pharmaceuticals, is…
-
Immunochina Pharmaceuticals Raises Funds for Gene Therapy Development
•
Beijing-based gene therapy specialist Immunochina Pharmaceuticals has reportedly raised “hundreds of millions” of renminbi in a Series D+ financing round, following a Series D financing round at the same scale in November 2021. The round was led by ZGC Science City and Beijing Innovation Industry Investment. The proceeds will be…
-
Immunochina Pharmaceuticals Secures CAR-T Production License in Beijing
•
Beijing-based Immunochina Pharmaceuticals has obtained a Drug Production License for its chimeric antigen receptor (CAR) T-cell therapies, making it the first company in Beijing and one of a few nationally to receive the certification as a gene therapy firm. Approval SignificanceThe license confirms that Immunochina’s facilities comply with quality regulations,…
